ABVC Current Deferred Revenue from 2010 to 2026
| ABVC Stock | USD 1.86 0.04 2.11% |
Current Deferred Revenue | First Reported 2007-06-30 | Previous Quarter 81.1 K | Current Value 81.1 K | Quarterly Volatility 1.6 M |
Check ABVC Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ABVC Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 997.3 K, Selling General Administrative of 4.9 M or Total Revenue of 615.3 K, as well as many indicators such as Price To Sales Ratio of 14.77, Dividend Yield of 0.0 or PTB Ratio of 4.8. ABVC financial statements analysis is a perfect complement when working with ABVC Biopharma Valuation or Volatility modules.
ABVC | Current Deferred Revenue | Build AI portfolio with ABVC Stock |
Analyzing ABVC Biopharma's Current Deferred Revenue over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Current Deferred Revenue has evolved provides context for assessing ABVC Biopharma's current valuation and future prospects.
Latest ABVC Biopharma's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of ABVC Biopharma over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. ABVC Biopharma's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ABVC Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
ABVC Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 29,649 | |
| Geometric Mean | 16,203 | |
| Coefficient Of Variation | 113.69 | |
| Mean Deviation | 27,441 | |
| Median | 13,085 | |
| Standard Deviation | 33,708 | |
| Sample Variance | 1.1B | |
| Range | 97.6K | |
| R-Value | 0.76 | |
| Mean Square Error | 514.9M | |
| R-Squared | 0.58 | |
| Significance | 0.0004 | |
| Slope | 5,062 | |
| Total Sum of Squares | 18.2B |
ABVC Current Deferred Revenue History
About ABVC Biopharma Financial Statements
ABVC Biopharma stakeholders use historical fundamental indicators, such as ABVC Biopharma's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although ABVC Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in ABVC Biopharma's assets and liabilities are reflected in the revenues and expenses on ABVC Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ABVC Biopharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 93.3 K | 97.9 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:Check out the analysis of ABVC Biopharma Correlation against competitors. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Will Biotechnology sector continue expanding? Could ABVC diversify its offerings? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ABVC Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.28) | Revenue Per Share | Quarterly Revenue Growth 1.045 | Return On Assets | Return On Equity |
Understanding ABVC Biopharma requires distinguishing between market price and book value, where the latter reflects ABVC's accounting equity. The concept of intrinsic value - what ABVC Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push ABVC Biopharma's price substantially above or below its fundamental value.
Understanding that ABVC Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ABVC Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, ABVC Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.